Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development By Investing.com

• Samsung (KS:) Biologics to offer ADC services at new dedicated facility
• Extended collaboration reflects successful partnership and expertise

INCHEON, South Korea, Jan. 8, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with LigaChem Biosciences (: 141080) to provide antibody-drug conjugate (ADC) services.

Samsung Biologics will support a series of  LigaChem Biosciences’ ADC programs at Samsung Biologics’ new dedicated  ADC facility. The two companies have already been collaborating on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a biotech pioneering research and development of ADC candidates.

“The latest collaboration will further strengthen Samsung Biologics’ capabilities across all stages of  ADC development and manufacturing as part of our commitment to deliver safe and high-quality…